April 2020

GlaxoSmithKline UK Ltd

Stockley Park West
Uxbridge
Middlesex
UB11 1BT

Tel. +44 (0)20 8990 9000
Fax. +44 (0)20 8990 4321
www.gsk.com

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

ReQuip (ropinorole hydrochloride) 0.25mg, 1mg, 2mg and 5mg Tablets: Important changes to the colour of carton and blister packs

Dear Pharmacist,

GlaxoSmithKline UK, in agreement with the Medicines and Healthcare Products Regulatory Agency (MHRA), would like to inform you of the following:

Summary

- **As a result of changes in the manufacturing process, and to standardise and harmonise the colours of the various strenths of Requip across different markets, there will be changes to the colour of the ink on both the cartons and blister packs of Requip.**
- **Whilst there is no impact on the medicine itself, GSK would like to draw this to your attention and encourage you to:**
    - **Take note of these important changes when dispensing ReQuip**
    - **Highlight the changes to your patients at the point of dispensing.**
- **Purpose: to mitigate against the risk of medication errors and any possible confusion to patients.**

Details

During 2019, important aspects of the manufacturing process for ReQuip changed, such that the yellow ink used for some blister packs was discontinued. In addition, the colours associated with different strengths of ReQuip have historically not been consistent across different markets/countries.

As a result of these factors, GSK made the decision to harmonise the colours of the different ReQuip strengths across all markets.

Content Lab code: NP-GB-NRU-LTR-200001 Date of Prep: 27 March 2020

In the UK this action will result in colour changes outlined in the table below:

Product	MA Number	Ink Colour OLD (UK)	Ink Colour NEW (UK)
ReQuip Tablets 0.25mg	PL 10592/0085	Blue	Cyan
ReQuip Tablets 1mg	PL 10592/0087	Yellow	Black
ReQuip Tablets 2mg	PL 10592/0088	Cyan	Red
ReQuip Tablets 5mg	PL 10592/0089	Black	Blue

The above changes to colours will apply to blister packs, and in addition, the colours of the various cartons have been modified to match the blister pack. These changes have been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA). The approximate dates that the new presentations with updated colours should be in circulation are as follows:

Product	MA Number	Approximate date to market (in chronological order)
ReQuip Tablets 1mg	PL 10592/0087	22-JUN-2020
ReQuip Tablets 2mg	PL 10592/0088	22-JUN-2020
ReQuip Tablets 0.25mg	PL 10592/0085	26-OCT-2020
ReQuip Tablets 5mg	PL 10592/0089	18-JAN-2021

Whilst there is no impact on the medicine itself, GSK would like to draw this to your attention and encourage you to highlight the changes to your patients at the point of dispensing, particularly as some new colours were previously associated with different strengths.

By highlighting and educating patients at the point of dispensing, any potential medication errors, and any possible confusion to patients should be mitigated.

Company contact point

Should you have any questions or require additional information, please contact GSK Medical Information Department at 0800-221-441.

Call for reporting

Adverse events associated with GSK medcines, including medication errors, should be reported according to the details below:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Yours Sincerely,

Dr Karen Mullen MBBS MRCP MFPM

Vice President

Country Medical Director UK & Ireland